INO-VATE: improving ALL outcomes with inotuzumab
The Phase III INO-VATE trial (NCT01564784) showed improved rates of complete remission and overall survival in relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
DaunoDouble: does increasing daunorubicin dose improve response in AML?
Daunorubicin is commonly used to treat acute myeloid leukemia (AML). In this video, Christoph Rllig, MD, of the University Hospital Carl Gustav Carus, Dresden, Germany, discusses the results from his...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
UKALL14: implementing genetics in ALL research
Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, discusses the current UKALL14 trial (NCT01085617) for adults aged 25-65 with acute lymphoblastic leukemia (ALL). The trial is the first of...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Support systems are a crucial factor in ALL treatment
Acute lymphoblastic leukemia (ALL) treatment regimens are long and debilitating, which is especially hard on young adults who are already going through a transitional phase of their lives; this makes ...
Author: VJHemOnc
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Next-generation methodologies: the future for MRD monitoring in ALL?
Measurable residual disease (MRD) is a significant prognostic factor in acute lymphoblastic leukemia (ALL), and as such it is important to establish standardized protocols to effectively detect and mo...
Author: VJHemOnc
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Emerging novel approaches for ALL: inotuzumab ozogamicin
The prognosis for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies are showing promising results. Here, Wendy St...
Author: VJHemOnc
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cell therapy for refractory multiple myeloma
CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid leukemia. Here, Nikhil Munshi, MD, from the Dana-Farber Cancer ...
Author: VJHemOnc
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Outstanding results from CLARITY: a new CLL combination therapy
The CLARITY study (ISCRTN13751862) is the first clinical trial looking at the combination of venetoclax and ibrutinib for treating relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Peter H...
Author: VJHemOnc
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Key MRD monitoring techniques in CLL
It is important that current techniques for the monitoring of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) are validated to ensure sensitivity and accuracy. Here, Peter Hillmen...
Author: VJHemOnc
Added: 07/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 13, 2018 Category: Cancer & Oncology Source Type: podcasts
The importance of MRD negativity as a predictive marker in CLL
Minimal residual disease (MRD) is the small number of leukemic cells that remain after treatment and there are no signs of cancer. However, it is a major cause of relapse, and as such, MRD eradication...
Author: VJHemOnc
Added: 07/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 13, 2018 Category: Cancer & Oncology Source Type: podcasts
A worldwide Phase III trial treating AML with pracinostat
Pracinostat has been shown to be an effective therapy for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in several Phase I and Phase II studies. Here, Guillermo Garcia-Mane...
Author: VJHemOnc
Added: 07/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Developments for the use of MRD in AML
This is a thrilling time for the use of measurable residual disease (MRD) in acute myeloid leukemia (AML), as highlighted here by Christopher Hourigan, MD, DPhil, of the National Heart, Lung, and Bloo...
Author: VJHemOnc
Added: 07/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 4, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD testing will be a part of future AML clinical trials
One big development in clinical trial design in acute myeloid leukemia (AML) is the inclusion of measurable residual disease (MRD) testing. In this interview, Christopher Hourigan, MD, DPhil, of the N...
Author: VJHemOnc
Added: 07/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 4, 2018 Category: Cancer & Oncology Source Type: podcasts
Moxetumomab pasudotox and hairy cell leukemia: results of a pivotal studyMoxetumomab pasudotox and hairy cell leukemia: results of a pivotal study
Robert Kreitman, MD, from the National Cancer Institute, Bethesda, MD, discusses a clinical trial using the recombinant immunotoxin, moxetumomab pasudotox, in patients with relapsed/refractory hairy c...
Author: VJHemOnc
Added: 06/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
There are a growing number of investigations of novel combination therapies for chronic lymphocytic leukemia (CLL). These are discussed in this interview with Peter Hillman, MD, ChB, from Leeds Teachi...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
